Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA Source: Eur Respir J 2012; 39: 1261-1263 Year: 2012
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005
Treatment of chronic pulmonary aspergillosis by voriconazole compared with micafungin Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus Year: 2009
Use of amphotericin B lipid complex in aspergillus infections of the lung: efficacy and safety Source: Eur Respir J 2001; 18: Suppl. 33, 304s Year: 2001
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy Source: Eur Respir J 2005; 25: 324-328 Year: 2005
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Impact of Aspergillus fumigatus infection on lung function in children with cystic fibrosis Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Intrabronchial voriconazole instillation provides effective hemoptysis control in inoperable pulmonary aspergilloma Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016
Pharmacokinetics of oral voriconazole in adults with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Source: Eur Respir J 2008; 31: 908-909 Year: 2008
Treatment outcome in patients with chronic pulmonary aspergillosis by azole-resistant aspergillus fumigatus Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016
Inhaled colistin following lung transplantation in colonised cystic fibrosis patients Source: Eur Respir J 2013; 42: 542-544 Year: 2013
Transmission-frequency of Aspergillus fumigatus in cystic fibrosis patients through coughing Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018